Pancreatic Ductal Adenocarcinoma Clinical Trials

53 studies are recruiting for pancreatic ductal adenocarcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

   The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Clearview Cancer Institute, Huntsville, Alabama

   Locations

   72 in total

   Run by

   Immuneering Corporation

   See if you can join NCT07562152 on ClinicalTrials.gov

2. The Use of Contrast Enhanced Ultrasound (CEUS) In Post-Surgical Pancreatic Cancer Patients to Evaluate Local Disease Recurrence

   This pilot study is testing whether a special type of ultrasound called contrast-enhanced ultrasound (CEUS) can help detect if pancreatic cancer has come back after surgery. People may be eligible to participate if they had surgery to remove pancreatic ductal adenocarcinoma (PDAC) from the head or …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

   Run by

   Thomas Jefferson University

   See if you can join NCT07910383 on ClinicalTrials.gov

3. Pancreatic Cancer Early Detection Consortium

   The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Honor Health Research Institute, Scottsdale, Arizona

   Locations

   62 in total

   Run by

   Arbor Research Collaborative for Health

   See if you can join NCT04970056 on ClinicalTrials.gov

4. A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

   Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA ( Site 0317), Los Angeles, California

   Locations

   55 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06428409 on ClinicalTrials.gov

5. 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

   Background: Fibroblast-activation protein (FAP) is an enzyme that appears in high numbers in cancer-associated fibroblasts of certain cancer types. [18F]FAPI-74 is a new PET (positron emission tomography) tracer, a substance that is injected into a person s body before an imaging scan. Researchers …

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06503146 on ClinicalTrials.gov

6. A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

   Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are looking for ways to stop the actions of abnormal proteins made from the mutated KRAS gene. ASP5834 is being studied in people with …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA Santa Monica Hematology Oncology, Santa Monica, California

   Locations

   22 in total

   Run by

   Astellas Pharma Inc

   See if you can join NCT07094204 on ClinicalTrials.gov

7. A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

   The purpose of this clinical study is to learn about the safety and effects of the study medicine (called PF-08098488) in people with advanced solid tumors (cancer that cannot be removed with surgery or has spread to other parts of the body). PF-08098488 is being studied as a possible treatment for…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Midwest, LLC, Grand Rapids, Michigan

   Locations

   2 in total

   Run by

   Pfizer

   See if you can join NCT07903415 on ClinicalTrials.gov

8. Lead-212 PSV359 Therapy for Patients With Solid Tumors

   Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

   Stage

   Phase 1

   Ages

   18 to 90

   Site

   VA Greater Los Angeles Healthcare System, Los Angeles, California

   Locations

   16 in total

   Run by

   Perspective Therapeutics

   See if you can join NCT06710756 on ClinicalTrials.gov

9. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

   This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast can…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   2 in total

   Run by

   Blue Earth Diagnostics

   See if you can join NCT07432633 on ClinicalTrials.gov

10. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars-Sinai Medical Center, Los Angeles, California

    Locations

    20 in total

    Run by

    Verastem, Inc.

    See if you can join NCT07020221 on ClinicalTrials.gov

11. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    88 in total

    Run by

    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

12. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest /ID# 283487, Grand Rapids, Michigan

    Locations

    3 in total

    Run by

    AbbVie

    See if you can join NCT07807956 on ClinicalTrials.gov

13. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center /ID# 258645, Duarte, California

    Locations

    54 in total

    Run by

    AbbVie

    See if you can join NCT06084481 on ClinicalTrials.gov

14. A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Developing Pancreatic Cancer

    This clinical trial studies a new screening program to improve the early detection of sporadic pancreatic cancer in individuals with a high risk of developing pancreatic cancer. Pancreatic cancer remains one of the deadliest solid tumors, characterized by a long phase without symptoms followed by r…

    Stage

    Not phased

    Ages

    50 to 85

    Site

    Mayo Clinic in Rochester, Rochester, Minnesota

    Run by

    Mayo Clinic

    See if you can join NCT07324096 on ClinicalTrials.gov

15. A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers

    Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these ducts. The goal of th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Hattiesburg Clinic /ID# 281952, Hattiesburg, Mississippi

    Locations

    7 in total

    Run by

    AbbVie

    See if you can join NCT07769502 on ClinicalTrials.gov

16. Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    United Theranostics, Princeton, New Jersey

    Locations

    9 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT07261631 on ClinicalTrials.gov

17. PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

    This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Hoag Memorial Hospital Presbyterian, Newport Beach, California

    Locations

    9 in total

    Run by

    PanTher Therapeutics

    See if you can join NCT06673017 on ClinicalTrials.gov

18. Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

    The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Texas Health Science Center at Houston, Houston, Texas

    Run by

    The University of Texas Health Science Center, Houston

    See if you can join NCT06831136 on ClinicalTrials.gov

19. AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

    The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2 .

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Research Site, Orange, California

    Locations

    52 in total

    Run by

    AstraZeneca

    See if you can join NCT06219941 on ClinicalTrials.gov

20. Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

    This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Patients with the following tumor types will be eligible for s…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California

    Locations

    11 in total

    Run by

    Phanes Therapeutics

    See if you can join NCT05482893 on ClinicalTrials.gov

21. Pancreatic Cancer Detection Consortium

    This study aims to prospective validate an exosome-based miRNA signature for noninvasive and early detection of pancreatic ductal adenocarcinoma.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Translational Genomics Research Institute, Phoenix, Arizona

    Locations

    13 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT06388967 on ClinicalTrials.gov

22. Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

    This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Jacksonville, Florida

    Locations

    25 in total

    Run by

    AstraZeneca

    See if you can join NCT06005493 on ClinicalTrials.gov

23. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Duarte, California

    Locations

    18 in total

    Run by

    AstraZeneca

    See if you can join NCT06218914 on ClinicalTrials.gov

24. Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma

    A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Imbert Cancer Center, Bay Shore, New York

    Locations

    7 in total

    Run by

    Northwell Health

    See if you can join NCT07163273 on ClinicalTrials.gov

25. UCSF PANC Cyst Registry

    Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are benign. Increased detection of pancreatic cysts provi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT04291651 on ClinicalTrials.gov